{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019679","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.971171+00:00","generated_at":"2026-06-15T11:43:09.022825+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Q1 net loss $9.0M; cash $16.6M; Phase 2 vaping cessation data positive; Phase 3 ORCA-3 topline due Q2","bullets":["Net loss of $9.0M for Q1 2023; cash, equivalents & restricted cash $16.6M as of March 31, 2023.","Phase 2 ORCA-V1 trial: cytisinicline 31.8% quit rate vs placebo 15.1%; 2.6x odds (p=0.035).","Phase 3 ORCA-3 trial (792 adults) fully enrolled; topline results expected Q2 2023.","Three new board members appointed: Stuart Duty, Thomas King, and Tom Sellig.","Shares outstanding: 18,040,760 as of May 9, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019679","json":"https://secwatch.observer/filing/0000950170-23-019679.json","markdown":"https://secwatch.observer/filing/0000950170-23-019679.md","text":"https://secwatch.observer/filing/0000950170-23-019679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017023019679/0000950170-23-019679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017023019679/achv-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:43:09.022825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"977407de60027ffda22a5365b3d268fbc0f8ae16","claim":"ACHIEVE LIFE SCIENCES, INC. reported the first quarter ended March 31, 2023 results: net income $9.0 million.","evidence_excerpt":"Total net loss for the first quarter ended March 31, 2023 was $9.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000095017023019679/0000950170-23-019679-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$9.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}